Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-TCR-T Cells in EB Virus Infection Diseases After HSCT
NCT04156217Phase 1Terminated
- Sponsor
- Lu Daopei Hospital
- Start
- Feb 2020
- Primary completion
- Jul 2021
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EBV TCR-T cells in Epstein-Barr virus infection and Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Lu Daopei Hospital. Primary endpoint: Percentage of adverse events at 3 months. Started Feb 2020; status: terminated.
02
Drugs
EBV TCR-T cells
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT04156217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156217.